Vertex Pharmaceuticals

Yahoo Finance • yesterday

Vertex Pharmaceuticals (VRTX) Surged on Increased Demand for its Cystic Fibrosis (CF) Franchise

GreensKeeper Asset Management, an investment management company, released its first quarter 2025 investor letter. A copy of the letter can be downloaded here. Markets had a difficult start to 2025; with high levels of volatility in all of... Full story

Yahoo Finance • 2 days ago

5 Top Growth Stocks to Buy in the Stock Market Sell-Off

Equity markets may be struggling because of President Donald Trump's current economic policies, but that doesn't mean investors should avoid buying stocks right now -- quite the contrary. History tells us that equities tend to experience s... Full story

Yahoo Finance • 3 days ago

Jim Cramer Calls Vertex Pharmaceuticals Incorporated (VRTX) “Terrific” With “Revolutionary Pain Drug”

We recently published a list of Jim Cramer Nailed These 11 Stock Picks. In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against other stocks that Jim Cramer discusses. On Thur... Full story

Yahoo Finance • 3 days ago

Is Vertex Pharmaceuticals Incorporated (VRTX) the Best Long Term Growth Stock to Buy According to Billionaires?

We recently published a list of 10 Best Long Term Growth Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against other best long term g... Full story

Yahoo Finance • 4 days ago

European Commission Approves Expanded Label for KAFTRIO® in Combination With Ivacaftor for People With Cystic Fibrosis

-Approximately 4,000 people living with CF in the European Union are newly eligible for a medicine that treats the underlying cause of their disease for the first time- LONDON, April 07, 2025--(BUSINESS WIRE)--Vertex Pharmaceuticals (Nasd... Full story

Yahoo Finance • 4 days ago

2 Stocks to Buy if You're Worried About a Recession

Is a recession coming? Our economic outlook seems increasingly gloomy due to President Trump's trade policies. Though things might not go that far, it's still worth planning ahead. If a recession does hit, it might also affect the stock m... Full story

Yahoo Finance • 11 days ago

Jim Cramer on Vertex Pharmaceuticals (VRTX): “Revolutionary Pain Drug on the Horizon!”

We recently published a list of Jim Cramer Looked At These 23 Stocks Recently. In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against other stocks that Jim Cramer looked at re... Full story

Yahoo Finance • 14 days ago

Is Vertex Pharmaceuticals (VRTX) The Most Expensive Stock Insiders Are Dumping In March?

We recently published a list of 20 Most Expensive Stocks Insiders Are Dumping In March. In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against other most expensive stocks insi... Full story

Yahoo Finance • 19 days ago

Jim Cramer on Vertex (VRTX): “A Revolutionary Anti-Pain Drug”

We recently published a list of Jim Cramer Discusses These 10 Stocks & Says US Faces Unfairly High Tariffs Abroad. In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against other... Full story

Yahoo Finance • 25 days ago

3 Unstoppable Stocks You Can Buy Now Without Any Hesitation

Are you reluctant to invest in stocks right now? That's understandable. Fear, uncertainty, and doubt have become the norm in early 2025 with rising stock market volatility. However, three Fool.com contributors think there are some unstopp... Full story

Yahoo Finance • 30 days ago

Should You Consider Adding Vertex Pharmaceuticals Incorporated (VRTX) to Your Portfolio?

Parnassus Investments, an investment management company, released the “Parnassus Core Equity Fund” fourth quarter 2024 investor letter. A copy of the letter can be downloaded here. In the fourth quarter, U.S. stocks rose, closing up a robu... Full story

Yahoo Finance • last month

Vertex Announces UK MHRA Approval of ALYFTREK® (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis

- Deutivacaftor/tezacaftor/vanzacaftor approved for people with cystic fibrosis 6 years and older with at least one responsive mutation in the CFTR gene, including additional mutations not previously approved with other CFTR modulator ther... Full story

Yahoo Finance • 2 months ago

High Growth Tech Stocks To Watch In February 2025

Over the last 7 days, the United States market has dropped 2.2%, yet it remains up by 18% over the past year with earnings expected to grow by 14% per annum in the coming years. In this context, identifying high growth tech stocks involves... Full story

Yahoo Finance • 2 months ago

Vertex Pharmaceuticals price target raised to $450 from $433 at Scotiabank

Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $450 from $433 and keeps a Sector Perform rating on the shares. The company had a strong Q4, with revenue beating consensus for Q4 and FY24, the analyst tells in... Full story

Yahoo Finance • 2 months ago

Vertex Pharmaceuticals price target raised to $520 from $460 at Truist

Truist raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $520 from $460 and keeps a Buy rating on the shares. The firm is positive on the launch of Journavx, which is seeing “broad based support even from political foes”,... Full story

Yahoo Finance • 2 months ago

Vertex Pharmaceuticals Inc (VRTX) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...

Revenue: $2.91 billion in Q4 2024, 16% growth versus Q4 2023. Full-Year Revenue: $11.02 billion for 2024, 12% growth versus 2023. Non-GAAP Operating Income: $1.2 billion in Q4 2024, compared to $1.15 billion in Q4 2023. Non-GAAP Earnings P... Full story

Yahoo Finance • 2 months ago

2 Biotech Stocks to Buy Hand Over Fist in February

Equity markets performed well in January, as they often do, but as the dust settles on that early-year run, the strategy for long-term investors remains the same: Invest in companies that can perform well over long periods, whether or not... Full story

Yahoo Finance • 2 months ago

AbbVie, Vertex's Journavx, Exxon and Chevron: Market Minute

Yahoo Finance host Josh Lipton breaks down the day's top trending stocks and market stories in the Market Minute. AbbVie (ABBV) shares continue to pop in Friday trading after raising its revenue guidance for new drugs Skyrizi and Rinvoq.... Full story

Yahoo Finance • 2 months ago

Vertex stock jumps on FDA approval of new non-opioid painkiller

Vertex Pharmaceuticals (VRTX) stock is rising following Food and Drug Administration (FDA) approval of Journavx, a non-opioid pain medication designed to treat moderate to severe acute pain. The new drug represents a potentially significan... Full story

Yahoo Finance • 2 months ago

How Painkillers Could Be Vertex Pharmaceuticals' Next $10 Billion Chapter

Vertex Pharmaceuticals could soon capture $10 billion in sales of non-opioid painkillers, an analyst said Friday as Vertex stock jumped. Continue Reading View Comments... Full story